Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (2): 236-241    DOI: 10.12892/ejgo4363.2019
Original Research Previous articles | Next articles
Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer
L. Bodnar1, *(), P. Knapp2, J. Sznurkowski3, R. Mądry4, A. Gąsowska-Bodnar5, M. Sikorska6, A. Timorek7, A. Ptak-Chmielewska8, R. Jach9, Polish Ovarian Cancer Group
1 Department of Oncology, Military Institute of Medicine, Warsaw, Poland
2 Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland
3 Department of Oncological Surgery, The Medical University of Gdańsk, Gdańsk, Poland
4 Clinic of Oncology, Poznan University of Medical Sciences, Poznan, Poland
5 Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, Poland
6 Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Warmia and Masuria, Poland
7 Department of Obstetrics, Gynecology, and Oncology, 2nd Faculty of Medicine, Warsaw Medical University and Brodnowski Hospital, Warsaw, Poland
8 Institute of Statistics and Demography, Warsaw School of Economics, Warsaw, Poland
9 Department of Gynecology and Oncology, Jagiellonian University College, Krakow, Poland
Download:  PDF(237KB)  ( 191 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: For patients with ovarian cancer (OC), the optimal time to initiate chemotherapy (TTC) after primary surgery is unknown. The aim of this study was to determine the effect of shorter TTC than 14 days on survival after primary surgery for OC among Polish women in 2011. Materials and Methods: All Polish women who underwent a surgical procedure for OC in the period from January 1, 2011 to December 31, 2011 recorded in the Polish National Health Fund Database (PNHFD) were included. The Cox proportional hazard regression analysis was used to compute the adjusted hazard ratio (HR). Results: The 25%, 50%, and 75% quantiles of intervals from surgery to TTC were 21, 30, and 43 days, respectively. In the multivariate analysis, it was observed that the adverse independent prognostic factors were: TTC ≤ 14 days [HR: 1.58 (95%CI: 1.24-2,01); p = 0.0002)] and a surgical procedure other than complex and very extensive excision of the upper part of the sex organs [HR: 2.02 (95%CI: 1.70-2.39); p < 0.0001]. The overall three-year survival rate for longer and shorter TTC than 14 days were 67.8% and 50.3%, respectively (p < 0.0001). Conclusions: This nationwide populationbased cohort study revealed a significantly increased risk of death in patients with TTC ≤ 14 days after primary surgery compared with a TTC > 14 days. In order to explain the causes of this phenomenon, it is necessary to conduct a prospective study that randomizes patients to different time intervals. Conclusions: The early initiation of chemotherapy after a primary surgery within 14 days is not a favourable prognostic factor. The nationwide population-based cohort study showed that complex and very extensive excision of the upper part of the sex organs due to ovarian cancer significantly decreased risk of death. In patients with ovarian cancer with comorbidities, the use of chemotherapy shortly, within 14 days, after surgery had unfavourable impact on survival.
Key words:  Ovarian cancer      Chemotherapy      Primary surgery      Prognostic factors     
Published:  10 April 2019     
*Corresponding Author(s):  L. BODNAR     E-mail:  lubo@esculap.pl

Cite this article: 

L. Bodnar, P. Knapp, J. Sznurkowski, R. Mądry, A. Gąsowska-Bodnar, M. Sikorska, A. Timorek, A. Ptak-Chmielewska, R. Jach, Polish Ovarian Cancer Group. Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer. European Journal of Gynaecological Oncology, 2019, 40(2): 236-241.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4363.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I2/236

[1] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[2] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[3] Yanan Li, Dongge Wang, Xiaodong Li, Wangchao Zhang, Xianghua Huang, Yibin Liu. Appendix invasion of squamous cell carcinoma arising from ovarian mature cystic teratoma and resistant to combination chemotherapy with docetaxel and oxaliplatin: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 841-844.
[4] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[5] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[6] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[7] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[8] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[9] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[10] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[11] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[12] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[13] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[14] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[15] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
No Suggested Reading articles found!